152 related articles for article (PubMed ID: 31376203)
1. Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: A case report and review of the literature.
Branco B; Comont T; Ysebaert L; Picard M; Laurent C; Oberic L
Eur J Haematol; 2019 Oct; 103(4):444-448. PubMed ID: 31376203
[No Abstract] [Full Text] [Related]
2. BRAF(V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia.
Michonneau D; Kaltenbach S; Derrieux C; Trinquand A; Brouzes C; Gibault L; North MO; Delarue R; Varet B; Emile JF; Brousse N; Hermine O
J Clin Oncol; 2014 Dec; 32(35):e117-21. PubMed ID: 24567436
[No Abstract] [Full Text] [Related]
3. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.
Idbaih A; Mokhtari K; Emile JF; Galanaud D; Belaid H; de Bernard S; Benameur N; Barlog VC; Psimaras D; Donadieu J; Carpentier C; Martin-Duverneuil N; Haroche J; Feuvret L; Zahr N; Delattre JY; Hoang-Xuan K
Neurology; 2014 Oct; 83(16):1478-80. PubMed ID: 25209580
[No Abstract] [Full Text] [Related]
4. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
5. BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition.
Obasaju P; Shahab S; Dunn E; Rhee DS; Jiang L; Dome JS; Friedman AD; Argani P; Pratilas CA
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238401
[TBL] [Abstract][Full Text] [Related]
6.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
7. What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?
Atkins MB
Clin Adv Hematol Oncol; 2016 Jun; 14(6):417-9. PubMed ID: 27379810
[No Abstract] [Full Text] [Related]
8. Secondary histiocytic sarcoma with BRAF
Venkataraman V; Massoth LR; Sullivan RJ; Friedmann AM
Pediatr Blood Cancer; 2021 Oct; 68(10):e29166. PubMed ID: 34061432
[No Abstract] [Full Text] [Related]
9. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
[TBL] [Abstract][Full Text] [Related]
10. Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
Voruz S; Cairoli A; Naveiras O; de Leval L; Missiaglia E; Homicsko K; Michielin O; Blum S
Haematologica; 2018 Jan; 103(1):e39-e41. PubMed ID: 29097496
[No Abstract] [Full Text] [Related]
11. Dramatic transient improvement of metastatic BRAF(V600E)-mutated Langerhans cell sarcoma under treatment with dabrafenib.
Mourah S; Lorillon G; Meignin V; Vercellino L; de Margerie-Mellon C; Pages C; Goldwirt L; How-Kit A; Tost J; Lebbe C; Tazi A
Blood; 2015 Dec; 126(24):2649-52. PubMed ID: 26468227
[No Abstract] [Full Text] [Related]
12. Targeting
Burkart J; Owen D; Shah MH; Abdel-Misih SRZ; Roychowdhury S; Wesolowski R; Haraldsdottir S; Reeser JW; Samorodnitsky E; Smith A; Konda B
J Natl Compr Canc Netw; 2018 Sep; 16(9):1035-1040. PubMed ID: 30181415
[TBL] [Abstract][Full Text] [Related]
13. BRAF-Directed Therapy in Metastatic Colorectal Cancer.
Korphaisarn K; Kopetz S
Cancer J; 2016; 22(3):175-8. PubMed ID: 27341594
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
Long G
Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501
[No Abstract] [Full Text] [Related]
15. BRAF
Vaughn JL; Freitag CE; Hemminger JA; Jones JA
J Med Case Rep; 2017 Apr; 11(1):92. PubMed ID: 28376906
[TBL] [Abstract][Full Text] [Related]
16. Trametinib and Dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation.
Rassidakis GZ; Stromberg O; Xagoraris I; Jatta K; Sonnevi K
Ann Hematol; 2020 Mar; 99(3):649-651. PubMed ID: 32009180
[No Abstract] [Full Text] [Related]
17. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.
Juratli TA; Jones PS; Wang N; Subramanian M; Aylwin SJB; Odia Y; Rostami E; Gudjonsson O; Shaw BL; Cahill DP; Galanis E; Barker FG; Santagata S; Brastianos PK
Cancer; 2019 Sep; 125(17):2910-2914. PubMed ID: 31314136
[TBL] [Abstract][Full Text] [Related]
18. BRAF(V600E) mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients.
Sellar RS; Fend F; Akarca AU; Agostinelli C; Shende V; Quintanilla-MartÃnez L; Stein H; Pileri SA; Linch D; Marafioti T
Br J Haematol; 2015 Jul; 170(2):282-5. PubMed ID: 25758903
[No Abstract] [Full Text] [Related]
19. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN
Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896
[TBL] [Abstract][Full Text] [Related]
20. MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.
Pietrantonio F; Oddo D; Gloghini A; Valtorta E; Berenato R; Barault L; Caporale M; Busico A; Morano F; Gualeni AV; Alessi A; Siravegna G; Perrone F; Di Bartolomeo M; Bardelli A; de Braud F; Di Nicolantonio F
Cancer Discov; 2016 Sep; 6(9):963-71. PubMed ID: 27325282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]